2 Information about pentosan polysulfate sodium

2 Information about pentosan polysulfate sodium

Marketing authorisation indication

Pentosan polysulfate sodium (Elmiron, Consilient Health) has a marketing authorisation for treating 'bladder pain syndrome characterised by either glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency and frequency of micturition'.

Dosage in the marketing authorisation

300 mg/day taken as 1 × 100-mg capsule orally 3 times daily.

Treatment is stopped if no improvement is reached 6 months after starting treatment. In people whose condition responds, treatment should be continued as long as the response is maintained. Response to treatment should be reassessed every 6 months.


A pack of 90 capsules (100 mg each) costs £450.

The company has a commercial arrangement. This makes pentosan polysulfate sodium available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)